Trial Profile
A Phase II Study of Afatinib in Patients With Advanced NSCLC Harboring HER2 Mutations, Previously Treated With Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 04 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 30 May 2018 Planned End Date changed from 31 Dec 2019 to 30 Jul 2019.
- 30 May 2018 Planned primary completion date changed from 30 Sep 2018 to 30 Jul 2018.